GEAP202316262A - Pharmaceutical compositions of a kinase inhibitor - Google Patents
Pharmaceutical compositions of a kinase inhibitorInfo
- Publication number
- GEAP202316262A GEAP202316262A GEAP202316262A GEAP2023016262A GEAP202316262A GE AP202316262 A GEAP202316262 A GE AP202316262A GE AP202316262 A GEAP202316262 A GE AP202316262A GE AP2023016262 A GEAP2023016262 A GE AP2023016262A GE AP202316262 A GEAP202316262 A GE AP202316262A
- Authority
- GE
- Georgia
- Prior art keywords
- pharmaceutical compositions
- kinase inhibitor
- methods
- relates
- pharmaceutical composition
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/472—Non-condensed isoquinolines, e.g. papaverine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2009—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2095—Tabletting processes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/2833—Organic macromolecular compounds
- A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
- A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Inorganic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063110124P | 2020-11-05 | 2020-11-05 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| GEAP202316262A true GEAP202316262A (en) | 2023-08-10 |
Family
ID=78820880
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| GEAP202316262A GEAP202316262A (en) | 2020-11-05 | 2021-11-04 | Pharmaceutical compositions of a kinase inhibitor |
Country Status (15)
| Country | Link |
|---|---|
| US (1) | US20230398108A1 (enExample) |
| EP (1) | EP4240333A1 (enExample) |
| JP (1) | JP7879109B2 (enExample) |
| KR (1) | KR20230104186A (enExample) |
| CN (1) | CN116406261A (enExample) |
| AU (1) | AU2021374669A1 (enExample) |
| CA (1) | CA3196001A1 (enExample) |
| CL (1) | CL2023001268A1 (enExample) |
| CO (1) | CO2023005942A2 (enExample) |
| CR (1) | CR20230223A (enExample) |
| GE (1) | GEAP202316262A (enExample) |
| IL (1) | IL302485A (enExample) |
| MX (1) | MX2023005273A (enExample) |
| PE (1) | PE20240223A1 (enExample) |
| WO (1) | WO2022098828A1 (enExample) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| HRP20251184T1 (hr) * | 2018-01-26 | 2025-12-05 | Exelixis, Inc. | Spojevi za liječenje poremećaja ovisnih o kinazi |
| AR127561A1 (es) * | 2021-11-03 | 2024-02-07 | Exelixis Inc | Compuestos para el tratamiento de trastornos dependientes de cinasas |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2012009722A1 (en) * | 2010-07-16 | 2012-01-19 | Exelixis, Inc. | C-met modulator pharmaceutical compositions |
| ES2927651T3 (es) * | 2013-04-04 | 2022-11-10 | Exelixis Inc | Forma de dosificación de cabozantinib y uso en el tratamiento del cáncer |
| WO2016079687A1 (en) * | 2014-11-18 | 2016-05-26 | Lupin Limited | Oral pharmaceutical composition of teriflunomide |
| HRP20251184T1 (hr) | 2018-01-26 | 2025-12-05 | Exelixis, Inc. | Spojevi za liječenje poremećaja ovisnih o kinazi |
| PL3894012T4 (pl) | 2018-12-13 | 2026-01-05 | Exelixis, Inc. | Postacie krystaliczne i postacie soli inhibitora kinazy |
| CN116473973A (zh) * | 2018-12-24 | 2023-07-25 | 正大天晴药业集团股份有限公司 | 吡咯并嘧啶化合物的治疗用途及其固体药物组合物 |
-
2021
- 2021-11-04 IL IL302485A patent/IL302485A/en unknown
- 2021-11-04 WO PCT/US2021/057996 patent/WO2022098828A1/en not_active Ceased
- 2021-11-04 KR KR1020237017606A patent/KR20230104186A/ko active Pending
- 2021-11-04 EP EP21819284.7A patent/EP4240333A1/en active Pending
- 2021-11-04 CA CA3196001A patent/CA3196001A1/en active Pending
- 2021-11-04 PE PE2023001561A patent/PE20240223A1/es unknown
- 2021-11-04 CN CN202180074166.6A patent/CN116406261A/zh active Pending
- 2021-11-04 MX MX2023005273A patent/MX2023005273A/es unknown
- 2021-11-04 CR CR20230223A patent/CR20230223A/es unknown
- 2021-11-04 GE GEAP202316262A patent/GEAP202316262A/en unknown
- 2021-11-04 AU AU2021374669A patent/AU2021374669A1/en active Pending
- 2021-11-04 US US18/035,355 patent/US20230398108A1/en active Pending
- 2021-11-04 JP JP2023526968A patent/JP7879109B2/ja active Active
-
2023
- 2023-05-03 CL CL2023001268A patent/CL2023001268A1/es unknown
- 2023-05-09 CO CONC2023/0005942A patent/CO2023005942A2/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| WO2022098828A1 (en) | 2022-05-12 |
| JP2023548855A (ja) | 2023-11-21 |
| IL302485A (en) | 2023-06-01 |
| CR20230223A (es) | 2023-07-07 |
| PE20240223A1 (es) | 2024-02-16 |
| EP4240333A1 (en) | 2023-09-13 |
| MX2023005273A (es) | 2023-05-23 |
| AU2021374669A1 (en) | 2023-06-15 |
| AU2021374669A9 (en) | 2024-04-18 |
| CO2023005942A2 (es) | 2023-05-19 |
| TW202227061A (zh) | 2022-07-16 |
| US20230398108A1 (en) | 2023-12-14 |
| JP7879109B2 (ja) | 2026-06-23 |
| CL2023001268A1 (es) | 2023-12-11 |
| CN116406261A (zh) | 2023-07-07 |
| KR20230104186A (ko) | 2023-07-07 |
| CA3196001A1 (en) | 2022-05-12 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2022015272A (es) | Inhibidores de la proteina kras g12c y usos de estos. | |
| PH12021551356A1 (en) | Crystalline forms and salt forms of a kinase inhibitor | |
| CO2025015814A2 (es) | Inhibidores de kras de 2-azabiciclo [2.2.1] heptano | |
| SA522431915B1 (ar) | Prmt5 مثبطات mta تعاونية مع | |
| MX2021005047A (es) | Compuestos de 6-azabenzimidazol sustituidos como inhibidores de hpk1. | |
| SA521422031B1 (ar) | مركبات 2 – فورميل – 3 – هيدروكسي فينيلوكسي ميثيل قادرة على تعديل الهيموجلوبين | |
| EA202191630A1 (ru) | ХИМИЧЕСКИ МОДИФИЦИРОВАННЫЕ КОНСТРУКЦИИ ДЛЯ RNAi И ПУТИ ИХ ПРИМЕНЕНИЯ | |
| CL2023001268A1 (es) | Composiciones farmacéuticas de un inhibidor de cinasa | |
| CL2021002681A1 (es) | Inhibidores de la dihidroorotato deshidrogenasa. | |
| MX2022014925A (es) | Moduladores de il-17a. | |
| BR112022022578A2 (pt) | Novas composições e métodos de tratar doença covid-19 | |
| BR112021024300A2 (pt) | Formas de sais cristalinas de um inibidor de quinase | |
| PH12022553019A1 (en) | Il-17a modulators | |
| GEAP202516611A (en) | Nlrp3 modulators | |
| MX2025008092A (es) | Inhibidores de kif18a y usos de los mismos | |
| MX2024002391A (es) | Inhibidores de indolina de kif18a. | |
| SA522441554B1 (ar) | Ripk1 مركبات أيزوكسازوليدين كمثبطات واستخدامها | |
| MX2023015408A (es) | Inhibidores de transglutaminasas. | |
| MX2025012370A (es) | Compuesto de amida, composicion farmaceutica que comprende el compuesto y uso de esta | |
| BR112022015925A2 (pt) | Combinações de compostos beta-lactâmicos, probenecida e ácido valproico e usos dos mesmos | |
| BR112022011527A2 (pt) | Compostos e uso dos mesmos para o tratamento de deficiência de a1-antitripsina | |
| ZA202211253B (en) | Compositions comprising 15-hepe for treating or preventing hematologic disorders, and/or related diseases | |
| JOP20210009A1 (ar) | طرق لعلاج HFpEF باستعمال داباجليفلوزين وتركيبات تشمله | |
| BR112022015869A2 (pt) | Composto, composição farmacêutica, métodos para inibir a ceto-hexoquinase e de tratamento e/ou prevenção de uma doença ou distúrbio, e, uso de um composto | |
| GEAP202516217A (en) | Compounds and compositions as sppl2a inhibitors |